Valneva: Marketing authorisation granted to Ixchiq in Europe

(CercleFinance.com) - Valneva announces that the European Commission has granted marketing authorisation (MA) to Ixchiq, its single-dose vaccine for the prevention of disease caused by the chikungunya virus in people aged 18 and over.


The authorisation of the vaccine was unanimously approved by member states following a rigorous evaluation by the European Medicines Agency (EMA), based on data from a pivotal Phase 3 study published in The Lancet.

Valneva thus receives a third MA for Ixchiq, following approvals from the US FDA and Health Canada. The company plans to deliver the first doses of the vaccine in Europe in the fourth quarter of 2024.


Copyright (c) 2024 CercleFinance.com. All rights reserved.